Bicycle Therapeutics plc (NASDAQ:BCYC) Stock Position Decreased by Wexford Capital LP

Wexford Capital LP lowered its holdings in Bicycle Therapeutics plc (NASDAQ:BCYC) by 22.3% during the third quarter, HoldingsChannel.com reports. The fund owned 34,879 shares of the company’s stock after selling 10,000 shares during the period. Wexford Capital LP’s holdings in Bicycle Therapeutics were worth $789,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of BCYC. Assetmark Inc. bought a new stake in shares of Bicycle Therapeutics during the third quarter valued at approximately $34,000. GAMMA Investing LLC increased its position in Bicycle Therapeutics by 105.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock valued at $46,000 after acquiring an additional 1,038 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in Bicycle Therapeutics by 69.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock valued at $162,000 after acquiring an additional 2,918 shares in the last quarter. XTX Topco Ltd acquired a new position in Bicycle Therapeutics during the 2nd quarter worth $206,000. Finally, Crossmark Global Holdings Inc. bought a new position in shares of Bicycle Therapeutics in the third quarter worth $257,000. 86.15% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BCYC has been the subject of several research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicycle Therapeutics in a report on Monday, September 9th. Stephens assumed coverage on shares of Bicycle Therapeutics in a report on Friday, November 8th. They issued an “equal weight” rating and a $25.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $55.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, November 1st. JMP Securities restated a “market outperform” rating and issued a $32.00 target price on shares of Bicycle Therapeutics in a research report on Monday, September 16th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $38.00 price target on shares of Bicycle Therapeutics in a research report on Thursday, October 31st. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Bicycle Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $40.13.

Bicycle Therapeutics Stock Down 2.4 %

Shares of NASDAQ BCYC opened at $19.21 on Friday. Bicycle Therapeutics plc has a 52-week low of $14.39 and a 52-week high of $28.67. The stock has a market capitalization of $913.44 million, a price-to-earnings ratio of -5.84 and a beta of 0.86. The stock’s fifty day simple moving average is $23.18 and its 200 day simple moving average is $22.87.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.04. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm had revenue of $2.68 million for the quarter, compared to the consensus estimate of $6.82 million. During the same quarter in the previous year, the company earned ($1.26) EPS. The business’s revenue for the quarter was down 50.0% compared to the same quarter last year. As a group, analysts anticipate that Bicycle Therapeutics plc will post -3.07 earnings per share for the current year.

Insider Activity

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,212 shares of Bicycle Therapeutics stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $22.26, for a total transaction of $71,499.12. Following the transaction, the chief executive officer now owns 380,864 shares of the company’s stock, valued at $8,478,032.64. The trade was a 0.84 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Travis Alvin Thompson sold 6,256 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $25.11, for a total transaction of $157,088.16. Following the completion of the sale, the chief accounting officer now directly owns 19,241 shares of the company’s stock, valued at $483,141.51. This trade represents a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,840 shares of company stock worth $259,128 over the last 90 days. 8.50% of the stock is owned by company insiders.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.